SCYNEXIS is on the Cruelty Free Investing list for exploiting animals because the company does animal testing in developing some of their medical and clinical analysis.
“SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a broad range of Candida and Aspergillus species, including drug resistant strains”
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. [Source: Reuters]
Company Website: http://www.scynexis.com/